Company intelligence / Profile preview
ADMA Biologics, Inc.
Ramsey, New Jersey, United Stateslinkedin.com ↗
- Ownership
- Public · ADMA
- Employees
- ~685
- Development stage
- Commercial
01
Overview
ADMA Biologics has three FDA-approved products on the market: ASCENIV, BIVIGAM, and NABI-HB. The company reported preliminary unaudited revenue of approximately $417-425 million for FY 2024, exceeding previous guidance of $415 million.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Plasma-derived biologicsImmune globulins
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $2.2B
- Total revenue
- $124.4M
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on ADMA Biologics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADMA Biologics, Inc..